INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
01Overview02Follow the Money03Daily Brief04Live05Congress06Directory07Corporate Insiders08Government Money09Political Influence10Institutions11Washington Network12Follow the Power13Disclosure Clock14AI Investigator15Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 433m ago
HOUSE PTR32m ago
SEC 13F32m ago
ROBINHOOD CHAIN32m ago
SEC FORM 4/Grant or awardVerified data

Miller Aine reported TBPH

SVP, DEV & HEAD OF IRE OFFICE · Theravance Biopharma, Inc. · Ordinary Shares

Side
A
Value
—
Shares
18.8K
Price
—
Executed
Jun 19, 2026
Disclosed
Jun 23, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Jun 19 executedJun 23, 2026 disclosed

TBPH · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
13/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+5 / 25

    No reported dollar value · 10.6% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · TBPH

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    32.7K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    22.0K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    23.6K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    SA
    Sawaf AzizSVP & CHIEF FINANCIAL OFFICER
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    23.4K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GA
    Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    23.4K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MA
    Miller AineSVP, DEV & HEAD OF IRE OFFICE
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    96.7K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    SA
    Sawaf AzizSVP & CHIEF FINANCIAL OFFICER
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    205.0K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    13.4K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    24.3K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    2
    FR
    Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    150.0K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    21
    MA
    Miller AineSVP, DEV & HEAD OF IRE OFFICE
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    93.1K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    MA
    Miller AineSVP, DEV & HEAD OF IRE OFFICE
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    37.5K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GA
    Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    223.9K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GA
    Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    107.8K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    SA
    Sawaf AzizSVP & CHIEF FINANCIAL OFFICER
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    108.4K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    2
    FR
    Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    124.4K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    2
    FR
    Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    89.1K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    6,009 sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    9
    GS
    Gray SusannahDirector
    TBPHTheravance Biopharma, Inc.
    Disposition to issuer
    		D—
    42.1K sh
    		Sep 23, 2026Sep 24, 2026
    traded Sep 23, 2026
    		+1dSEC FORM 4

    Evidence

    1
    FR
    Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
    TBPHTheravance Biopharma, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$57K
    3,328 sh
    		Sep 15, 2026Sep 17, 2026
    traded Sep 15, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002012524-26-000006
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Jun 19, 2026
    Published
    Jun 23, 2026
    Ingested by INSIDER
    Nov 5, 03:51 UTC
    Last re-read
    Nov 5, 03:51 UTC

    Extracted facts

    Filer
    Miller Aine
    Role
    SVP, DEV & HEAD OF IRE OFFICE
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Theravance Biopharma, Inc.
    Ticker
    TBPH
    Shares
    18.8K
    Price per share
    $0
    Execution date (reported)
    Jun 19, 2026
    Owned after transaction
    196.1K shares
    Days from execution to publication
    4

    What this establishes

    Miller Aine filed this Form 4 reporting a grant or award of TBPH on Jun 19, 2026. It became public on Jun 23, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP, DEV & HEAD OF IRE OFFICE
    Miller Ainecik:0002012524
    Issuer
    Theravance Biopharma, Inc.cik:0001583107

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.